Core Viewpoint - Unilever's current CEO Hein Schumacher will officially resign on March 1, 2024, with CFO Fernando Fernandez set to take over, raising concerns about the unfinished aggressive reforms during Schumacher's tenure and the company's stagnant performance [1][5]. Group 1: Leadership Changes - Hein Schumacher, who took over as CEO in July 2023, is known for his aggressive reform approach, having previously led significant changes at FrieslandCampina and Heinz [2][3]. - During Schumacher's tenure, over half of Unilever's leadership team underwent changes, including key positions such as CFO and heads of various business units [3]. Group 2: Reform Initiatives - Schumacher introduced the "Growth Action Plan" shortly after his appointment, which included divesting non-core businesses, laying off 7,500 employees, and optimizing the brand portfolio [2]. - The reforms were seen as radical compared to Unilever's previous more conservative approaches to growth and sustainability [3][4]. Group 3: Performance Metrics - Despite some successes, such as record sales in 2024 and strong growth in the beauty segment, overall performance remained lackluster, with total sales reaching €60.8 billion, a 1.9% increase, while operating profit fell by 3.7% to €9.4 billion [5]. - The Asia-Pacific region accounted for 42.8% of Unilever's revenue in 2024, but the Chinese market experienced a decline, highlighting ongoing challenges [6][7]. Group 4: Future Challenges - New CEO Fernando Fernandez faces the challenge of restoring growth, particularly in the crucial Chinese market, where strategies will focus on enhancing business capabilities and leveraging e-commerce [6][7]. - Industry experts note that Unilever's multi-brand strategy in the beauty sector may not provide a competitive edge, especially as the Chinese beauty market undergoes significant changes [7].

Core Insights - The beauty industry is undergoing a technological transformation, with the integration of medical research driving value upgrades in cosmetics. This dual integration of medicine and beauty is defining a new competitive logic in the industry [3][6][24]. Industry Trends - The 20th China Dermatology Association (CDA) conference showcased over 10,000 dermatologists and more than 100 companies, including both domestic and international beauty brands, highlighting the industry's focus on scientific collaboration [3][4]. - The concept of "medical-research co-creation" emerged as a key theme, with brands actively participating in discussions on how to contribute to the skin science system, moving from mere users of research to active participants in scientific understanding and industry standards [7][24]. Brand Innovations - Winona, a brand known for its scientific foundation, showcased its "NUTE" principle at CDA 2025, which emphasizes clinical needs, unique mechanisms, technology empowerment, and credible evidence in product development [10]. - HBN, a domestic skincare brand, initiated the establishment of a group standard for "Cosmetic Efficacy Evidence Weight Assessment Guidelines," aiming to shift the industry from experience-driven to evidence-based competition [11][13]. - Estee Lauder's Clinique presented a white paper on the causes and distribution patterns of post-inflammatory hyperpigmentation, demonstrating the brand's commitment to scientific validation [14][16]. Research and Development - The integration of research and clinical application is evident in the initiatives taken by brands like Giant Bio and Zhenyan Bio, which are expanding the boundaries of medical-research co-creation through innovative collagen products and clinical studies [20][22]. - The collaboration between brands and medical experts is evolving, with companies like Ximu Yuan conducting extensive research on sensitive skin, showcasing a shift from being mere users of research to contributors to scientific inquiry [24][25]. Future Outlook - The CDA conference highlighted a significant shift in the beauty industry towards a more scientific and collaborative approach, with brands, medical institutions, and research organizations forming a new ecosystem that emphasizes shared data and mutual advancement [47][48]. - The focus on original ingredient research is becoming a core strategy for leading domestic brands, as they aim to differentiate themselves from homogenized competition [38][39].

Core Insights - The global beauty market is undergoing transformation amidst resilience, with the top ten beauty companies showing mixed performance in sales and growth [1][10] - The overall sales of the top ten beauty companies reached 824.69 billion RMB in the first three quarters of 2023, a 5.3% increase from 783.42 billion RMB in the same period last year [1][2] Sales Performance - L'Oréal leads the ranking with a sales figure of 269.99 billion RMB, marking a 1.2% increase [2] - Unilever follows with 160.49 billion RMB, but experienced a decline of 3.5% [2] - Procter & Gamble and Estée Lauder reported sales of 80.91 billion RMB and 74.35 billion RMB, respectively, with growth rates of 1.4% and a decline of 6.6% [2][3] - Only L'Oréal, Procter & Gamble, and Puig showed sales growth among the top ten companies, while Coty experienced the largest decline at 6.7% [3] Strategic Adjustments - Companies like Unilever and Coty are undergoing significant strategic changes, including layoffs and asset divestitures, to adapt to market conditions [4] - Estée Lauder has initiated a "Reinventing Beauty" plan to restructure its operations and brand management [4] High-End Beauty Market - The high-end beauty market is showing signs of recovery, with Estée Lauder reporting a 4% increase in net sales in Q3 2023 [7][8] - L'Oréal's growth in the high-end skincare segment in China has been a significant driver of its performance [8][10] China Market Dynamics - The Chinese market is emerging as a new growth engine for international beauty companies, with Coty reporting a 15% increase in high-end beauty sales in China [10][11] - Procter & Gamble's sales in the Greater China region grew by 5%, indicating a positive trend [10][11] - Estée Lauder has begun to treat the Chinese mainland as a separate reporting region, highlighting its importance [11] Future Outlook - The global beauty market is in a phase of adjustment, with high-end beauty recovery and the Chinese market's resurgence being key factors for future growth [10][11] - Companies that can adapt to changing consumer demands and leverage digital transformation are likely to succeed in the evolving competitive landscape [11]

Core Viewpoint - Doubts have arisen regarding the future role of Anuradha Mittal as chair of Ben & Jerry's board in the context of its parent company Unilever's ice cream spin-off, The Magnum Ice Cream Company (TMICC) [1][4]. Group 1: Leadership Changes - Anuradha Mittal joined Ben & Jerry's in 2007 and became the independent chair in 2018, prior to Unilever's acquisition of the company [2]. - The SEC filing suggests that Mittal may no longer meet the criteria to serve on the Ben & Jerry's board, following internal investigations [4]. Group 2: Disputes and Autonomy - The situation escalated after co-founder Jerry Greenfield's departure amid disputes with Unilever over the company's autonomy and adherence to its social values [3]. - Cohen and Greenfield have expressed concerns about Unilever's influence, requesting that Ben & Jerry's operate as an independently owned company rather than being absorbed into TMICC [7]. Group 3: Potential Legal Actions - The SEC filing indicates that the group may consider legal actions against TMICC and/or Unilever based on the results of the internal investigations [5]. - There is a possibility that the Ben & Jerry's board may initiate proceedings against the group or its employees as a response to the findings [6].

Core Viewpoint - The Magnum Ice Cream Company has determined that the chair of Ben & Jerry's independent board no longer meets the criteria to serve, following internal investigations, indicating escalating tensions between the two brands as Unilever prepares for the spin-off of the Magnum division [1][2][3]. Group 1: Internal Investigations and Board Changes - Magnum's filing states that after investigations by external advisers, the current chair of Ben & Jerry's is deemed unfit to serve on the board [3]. - The nature of the investigations has not been disclosed, raising questions about the implications for Ben & Jerry's governance [3][5]. - Magnum has communicated its findings to Ben & Jerry's board and is awaiting a response to determine its next steps [5]. Group 2: Background and Context - Ben & Jerry's independent board, chaired by Anuradha Mittal, has been involved in advocacy on controversial topics, which has drawn criticism from Unilever [4]. - The merger agreement from 2000 stipulates that replacing board members requires a majority vote, complicating Magnum's ability to enforce changes [6]. - Tensions between Unilever and Ben & Jerry's have been ongoing since 2021, particularly regarding the brand's stance on political issues, including its decision to stop sales in the Israeli-occupied West Bank [7].

Core Viewpoint - The company is set to list on the Euronext Amsterdam, NYSE, and London Stock Exchanges on December 6, demonstrating resilience in moving forward despite the U.S. government shutdown [1] Group 1 - The company will be listed on multiple stock exchanges, indicating a strategic move to enhance its market presence [1] - The listing date is confirmed for December 6, which is a significant milestone for the company [1] - The company has found a way to proceed with its plans despite external challenges such as the U.S. government shutdown [1]

Group 1: Magnum Ice Cream Co (MICC) Demerger and Listing - Magnum Ice Cream Co (MICC) is preparing for a triple listing on the London Stock Exchange, New York Stock Exchange, and Euronext Amsterdam, following its demerger from Unilever, expected in mid-November 2025 [1][2] - The demerger process is projected to incur costs of €800 million, with approximately 55% of these costs already incurred [1] - Unilever will retain a minority stake of less than 20% in Magnum for up to five years, which will be sold to cover separation costs and maintain capital flexibility [2] - Magnum reported €7.9 billion in revenue and €1.3 billion in adjusted EBITDA for 2024, holding an approximate 21% global retail market share [2] - The company has established a stable dividend policy, targeting a payout ratio of 40-60% of adjusted net income, with the first dividend expected in the first half of 2027 [2] Group 2: Corporate Earnings - Amgen (AMGN) reported a 12.4% year-on-year increase in sales to $9.56 billion, driven by strong performance from new inflammation drugs and cholesterol therapy Repatha [7] - Following its strong performance, Amgen raised its full-year profit and revenue guidance, with adjusted EPS now expected between $20.60 and $21.40 and revenue between $35.8 billion and $36.6 billion [7] - Super Micro Computer (SMCI) issued a weak profit forecast for the current quarter, adjusting its first-quarter fiscal 2026 revenue estimate to approximately $5 billion, down from $6-$7 billion [8] - Despite the short-term setback, Super Micro maintained its full-year revenue forecast of at least $33 billion, citing strong AI demand and a $12 billion backlog of new orders [8] - AMD (AMD) beat its Q3 expectations with revenues of $9.25 billion and adjusted EPS of $1.20, but its Q4 outlook did not meet investor expectations [8] Group 3: Canada's Financial Sector Reforms - Canada's government is targeting competition within its financial sector by tackling fees, simplifying the process for consumers to switch banks, and reducing regulatory burdens for smaller lenders [9] - The initiative includes prohibiting investment and registered account transfer fees, which currently cost Canadians an average of $150 per account [9] - The government plans to increase the amount of immediately available deposited cheque funds to $150 from $100 [9] Group 4: Economic Indicators - New Zealand's unemployment rate for Q3 rose to 5.3%, with no employment growth quarter-over-quarter and a year-over-year decline of -0.6% [11] - In the United States, API crude oil inventories surged by 6.5 million barrels, significantly exceeding forecasts that anticipated a draw of 2.4 million barrels [12]

Corporate Action - Unilever's ice cream spinoff's trading debut faces shutdown delay [1]

Core Viewpoint - Unilever expects to complete the spin-off of its Magnum Ice Cream unit by December 6, following a delay due to the U.S. government shutdown [1] Company Summary - The spin-off of the Magnum Ice Cream unit is part of Unilever's strategic restructuring efforts [1] - The completion date of December 6 indicates a timeline for investors and stakeholders to anticipate the finalization of this corporate action [1]

Group 1 - European companies are demonstrating remarkable adaptability to U.S. tariff barriers, with a Goldman Sachs portfolio of affected European stocks outperforming the market by approximately 6% in October, double the gain of the Stoxx Europe 600 index [1] - Major European firms like Hermès, Unilever, and Galderma Group AG attribute their better-than-expected performance and raised guidance to strong demand in the U.S. market [1][2] - The frequency of the term "tariff" in earnings calls is decreasing, indicating that corporate management's concerns about tariffs are diminishing [1] Group 2 - The U.S. market has become a key growth driver for many European companies, with Hermès reporting a 14.1% sales increase in its regional markets, and Unilever crediting strong North American demand for its sales performance [2] - Galderma raised its full-year guidance based on strong U.S. sales, while other companies like Haleon Plc and Stellantis also reported unexpected sales growth in North America [2] Group 3 - Companies are adapting to tariff challenges by cutting costs, adjusting production layouts, and increasing investments in the U.S. [3] - Pharmaceutical companies like Novartis and GSK are negotiating with the U.S. government for price reductions in exchange for future tariff exemptions, with AstraZeneca reaching an agreement in October [3] Group 4 - Despite overall optimism, the impact of tariffs is not uniform, with some companies like Rémy Cointreau and Pernod Ricard warning of weaker-than-expected recovery in specific markets [4] - Market sentiment is shifting towards the view that tariffs are manageable, although some analysts caution against premature conclusions regarding their impact [4][5]